Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Segments Reporting) (Details)

v3.22.1
Segment Reporting (Segments Reporting) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Mar. 31, 2022
Mar. 31, 2021
Nov. 01, 2021
Sep. 10, 2021
Jun. 30, 2021
Segment Reporting Information [Line Items]                      
Revenues - external customers $ 1,943,000     $ 765,000     $ 2,322,000 $ 1,880,000      
Cost of goods sold 48,000     493,000     201,000 1,275,000      
Gross profit 1,895,000     272,000     2,121,000 605,000      
Research and development 5,551,000     2,162,000     11,393,000 6,892,000      
General and administrative 8,526,000     5,313,000     23,522,000 15,385,000      
Operating loss (12,182,000)     (7,203,000)     (32,794,000) (21,672,000)      
Interest expense (250,000)     (612,000)     (1,187,000) (1,841,000)      
Forgiveness of note payable and accrued interest 0     0     607,000 0      
Interest and other income 42,000     153,000     124,000 186,000      
Consolidated net loss (12,390,000) $ (11,920,000) $ (8,940,000) (7,662,000) $ (8,131,000) $ (7,534,000) (33,250,000) (23,327,000)      
Total assets 115,370,000     142,697,000     115,370,000 142,697,000     $ 146,968,000
Finance lease ROU assets 86,000     26,380,000     86,000 26,380,000     26,111,000
Operating lease ROU assets 5,151,000           5,151,000   $ 1,967,000 $ 3,603,000 0
Fixed assets, net 34,581,000     6,407,000     34,581,000 6,407,000     8,628,000
Intangible assets, net 4,919,000     1,146,000     4,919,000 1,146,000     $ 952,000
Amortization of finance lease ROU assets 24,000     406,000     587,000 1,236,000      
Depreciation of fixed assets 709,000     119,000     1,532,000 330,000      
Amortization of intangible assets 122,000     73,000     333,000 218,000      
Operating Segments [Member] | Biopharmaceuticals (iBio, Inc.) [Member]                      
Segment Reporting Information [Line Items]                      
Revenues - external customers 1,800,000     700,000     1,884,000 1,097,000      
Revenues - intersegment 817,000     191,000     993,000 667,000      
Cost of goods sold       229,000       425,000      
Gross profit 2,617,000     662,000     2,877,000 1,339,000      
Research and development 3,764,000     1,500,000     7,498,000 2,341,000      
General and administrative 5,430,000     3,438,000     13,746,000 8,921,000      
Operating loss (6,577,000)     (4,276,000)     (18,367,000) (9,923,000)      
Interest and other income 40,000     153,000     117,000 185,000      
Consolidated net loss (6,538,000)     (4,123,000)     (18,251,000) (9,738,000)      
Total assets 165,896,000     165,096,000     165,896,000 165,096,000      
Operating lease ROU assets 3,209,000           3,209,000        
Fixed assets, net 1,068,000           1,068,000        
Intangible assets, net 4,919,000     1,146,000     4,919,000 1,146,000      
Amortization of intangible assets 122,000     73,000     333,000 218,000      
Operating Segments [Member] | Bioprocessing (iBio CDMO) [Member]                      
Segment Reporting Information [Line Items]                      
Revenues - external customers 143,000     65,000     438,000 783,000      
Revenues - intersegment 604,000     688,000     1,489,000 1,186,000      
Cost of goods sold 48,000     264,000     201,000 850,000      
Gross profit 699,000     489,000     1,726,000 1,119,000      
Research and development 2,416,000     1,353,000     5,432,000 5,761,000      
General and administrative 3,888,000     2,062,000     10,721,000 7,106,000      
Operating loss (5,605,000)     (2,927,000)     (14,427,000) (11,749,000)      
Interest expense (250,000)     (612,000)     (1,187,000) (1,841,000)      
Forgiveness of note payable and accrued interest             607,000        
Interest and other income 2,000           7,000 1,000      
Consolidated net loss (5,852,000)     (3,539,000)     (14,999,000) (13,589,000)      
Total assets 40,429,000     35,123,000     40,429,000 35,123,000      
Finance lease ROU assets 86,000     26,380,000     86,000 26,380,000      
Operating lease ROU assets 1,942,000           1,942,000        
Fixed assets, net 33,513,000     6,407,000     33,513,000 6,407,000      
Amortization of finance lease ROU assets 24,000     406,000     587,000 1,236,000      
Depreciation of fixed assets 709,000     119,000     1,532,000 330,000      
Eliminations [Member]                      
Segment Reporting Information [Line Items]                      
Revenues - intersegment (1,421,000)     (879,000)     (2,482,000) (1,853,000)      
Gross profit (1,421,000)     (879,000)     (2,482,000) (1,853,000)      
Research and development (629,000)     (691,000)     (1,537,000) (1,210,000)      
General and administrative (792,000)     (187,000)     (945,000) (642,000)      
Total assets $ (90,955,000)     $ (57,522,000)     $ (90,955,000) $ (57,522,000)